Market cap
$156 Mln
Revenue (TTM)
$84 Mln
P/E Ratio
--
P/B Ratio
20.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -6.92 | -19.48 | 2.19 | 4.27 | 5.23 |
| EBIT | -300.71 | -194.56 | -89.40 | 26.08 | 15.03 |
| Net Profit | -3,913.68 | -552.08 | -30.91 | 22.12 | 8.50 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Nov-24 | Nov-23 |
| EBIT-Margin
| -20.16 | -24.78 | 0.22 | 4.80 | -14.95 |
| Net Margin
| -- | -- | -10.85 | -- | -- |
| Return on equity
| 703.34 | 329.21 | -- | 36.00 | 110.30 |
| Return on Capital
| -55.44 | -48.49 | -- | -28.43 | -58.26 |
| Return on Assets
| -28.38 | -26.98 | -8.61 | -12.67 | -28.02 |
| Debt to Equity (x)
| -- | -- | -1.41 | -1.80 | -2.83 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Nov-24
|
Nov-23
|
Nov-22
|
Nov-21
|
Nov-20
|
Nov-19
|
Nov-18
|
Nov-17
|
Nov-16
|
Nov-15
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
|
--
|
36.00
|
110.30
|
1,963.71
|
-302.37
|
-161.57
|
|||||
|
Peer Median
|
-5.39
|
--
|
--
|
--
|
--
|
--
|
ROA
-8.61
Lower than Peers by 3.56
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Nov-24
|
Nov-23
|
Nov-22
|
Nov-21
|
Nov-20
|
Nov-19
|
Nov-18
|
Nov-17
|
Nov-16
|
Nov-15
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
|
-8.61
|
-12.67
|
-28.02
|
-44.46
|
-28.93
|
-20.82
|
|||||
|
Peer Median
|
-5.06
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
0.22
Higher than Peers by 7.53
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Nov-24
|
Nov-23
|
Nov-22
|
Nov-21
|
Nov-20
|
Nov-19
|
Nov-18
|
Nov-17
|
Nov-16
|
Nov-15
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
|
0.22
|
4.80
|
-14.95
|
-50.34
|
-37.23
|
-26.17
|
|||||
|
Peer Median
|
-7.31
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-10.85
Lower than Peers by 10.41
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Nov-24
|
Nov-23
|
Nov-22
|
Nov-21
|
Nov-20
|
Nov-19
|
Nov-18
|
Nov-17
|
Nov-16
|
Nov-15
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
|
-10.85
|
-9.67
|
-29.30
|
-59.00
|
-45.44
|
-34.32
|
|||||
|
Peer Median
|
-0.44
|
--
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
Revenue Growth
2.19
Lower than Peers by 15.82
Year on year growth in net sales
EBIT Growth
-89.40
Lower than Peers by 99.68
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Nov-24
|
Nov-23
|
Nov-22
|
Nov-21
|
Nov-20
|
Nov-19
|
Nov-18
|
Nov-17
|
Nov-16
|
Nov-15
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
|
-89.40
|
133.70
|
69.67
|
-55.00
|
-50.37
|
-130.34
|
|||||
|
Peer Median
|
10.28
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-30.91
Lower than Peers by 82.99
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Nov-24
|
Nov-23
|
Nov-22
|
Nov-21
|
Nov-20
|
Nov-19
|
Nov-18
|
Nov-17
|
Nov-16
|
Nov-15
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Theratechnologies (THTX)
|
-30.91
|
65.33
|
49.28
|
-48.90
|
-39.96
|
-81.39
|
|||||
|
Peer Median
|
52.09
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-1.41
--
Total debt / Net worth
Short term debt to equity ratio
-0.13
--
(Short term borrowings / Net worth)
Current Ratio
0.84
Lower than Peers by 4.44
Current Assets / Current Liabilities and Provisions
Quick Ratio
0.65
Lower than Peers by 4.67
(Current Assets - Inventory) / Current Liabilities and Provisions
Interest Coverage
0.07
Lower than Peers by 1.12
Earning before interest and taxes (EBIT) / Interest Expenses
Operating Efficiency
Debtors to sales
13.48
Lower than Peers by 9.39
Debtors outstanding / Net Sales * 100
Asset Turnover
0.79
Higher than Peers by 0.68
Sales / Average Total Assets
Receivable days
--
--
Average Debtors / Sales * 365
Inventory Days
--
--
Average Inventory / Sales * 365
Payable days
--
--
Average Creditors / Cost of goods sold * 365
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
Valuation
Price / Book Value
20.13
Higher than Peers by 16.49
Current share price divided by book value per share in the latest financial year
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
EV/EBITDA
74.63
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
Market Cap
156
Higher than Peers by 53
Current Share price multiplied by latest total number of shares outstanding